Industry News

Ocugen initiates Phase 3 clinical trial for OCU400 gene therapy for retinitis pigmentosa

Ocugen, Inc announced the first patient has been dosed in the Phase 3 LIMELIGHT clinical trial for OCU400, a novel gene therapy designed to treat retinitis pigmentosa (RP), a group of rare, genetic disorders that lead to progressive vision loss and blindness, according to a press release. This marks the...